These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 28088906)

  • 1. Epratuzumab and Blinatumomab as Therapeutic Antibodies for Treatment of Pediatric Acute Lymphoblastic Leukemia: Current Status and Future Perspectives.
    Franca R; Favretto D; Granzotto M; Decorti G; Rabusin M; Stocco G
    Curr Med Chem; 2017; 24(11):1050-1065. PubMed ID: 28088906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.
    Buie LW; Pecoraro JJ; Horvat TZ; Daley RJ
    Ann Pharmacother; 2015 Sep; 49(9):1057-67. PubMed ID: 26041811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blinatumomab for the treatment of adult acute lymphoblastic leukemia.
    Dahl J; Mace M; Kantarjian H; Jabbour E
    Drugs Today (Barc); 2015 Apr; 51(4):231-41. PubMed ID: 26020065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia.
    Bumma N; Papadantonakis N; Advani AS
    Future Oncol; 2015; 11(12):1729-39. PubMed ID: 26075441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights from the Greek experience of the use of Blinatumomab in pediatric relapsed and refractory acute lymphoblastic leukemia patients.
    Ampatzidou M; Kattamis A; Baka M; Paterakis G; Anastasiou T; Tzanoudaki M; Kaisari A; Avgerinou G; Doganis D; Papadakis V; Kitra V; Polychronopoulou S
    Neoplasma; 2020 Nov; 67(6):1424-1430. PubMed ID: 32701357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
    von Stackelberg A; Locatelli F; Zugmaier G; Handgretinger R; Trippett TM; Rizzari C; Bader P; O'Brien MM; Brethon B; Bhojwani D; Schlegel PG; Borkhardt A; Rheingold SR; Cooper TM; Zwaan CM; Barnette P; Messina C; Michel G; DuBois SG; Hu K; Zhu M; Whitlock JA; Gore L
    J Clin Oncol; 2016 Dec; 34(36):4381-4389. PubMed ID: 27998223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia.
    Jabbour E; Pui CH; Kantarjian H
    JAMA Oncol; 2018 Oct; 4(10):1413-1420. PubMed ID: 29931220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment.
    Demosthenous C; Lalayanni C; Iskas M; Douka V; Pastelli N; Anagnostopoulos A
    Curr Probl Cancer; 2019 Jun; 43(3):222-227. PubMed ID: 29895435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia.
    Le Jeune C; Thomas X
    Drug Des Devel Ther; 2016; 10():757-65. PubMed ID: 26937176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of blinatumomab, a novel immunotherapy.
    Newman MJ; Benani DJ
    J Oncol Pharm Pract; 2016 Aug; 22(4):639-45. PubMed ID: 26607163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blinatumomab, a Bispecific T-cell Engager (BiTE(®)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications.
    Zhu M; Wu B; Brandl C; Johnson J; Wolf A; Chow A; Doshi S
    Clin Pharmacokinet; 2016 Oct; 55(10):1271-1288. PubMed ID: 27209293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
    Topp MS; Gökbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA; Neumann S; Foà R; Litzow M; Ribera JM; Rambaldi A; Schiller G; Brüggemann M; Horst HA; Holland C; Jia C; Maniar T; Huber B; Nagorsen D; Forman SJ; Kantarjian HM
    Lancet Oncol; 2015 Jan; 16(1):57-66. PubMed ID: 25524800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blinatumomab for the treatment of acute lymphoblastic leukemia.
    Kaplan JB; Grischenko M; Giles FJ
    Invest New Drugs; 2015 Dec; 33(6):1271-9. PubMed ID: 26383529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibody-based therapies in the treatment of acute lymphoblastic leukemia.
    Litzow MR
    Am Soc Clin Oncol Educ Book; 2013; ():294-9. PubMed ID: 23714527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific antibodies in acute lymphoblastic leukemia therapy.
    Chitadze G; Laqua A; Lettau M; Baldus CD; Brüggemann M
    Expert Rev Hematol; 2020 Nov; 13(11):1211-1233. PubMed ID: 33000968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful use of blinatumomab in a patient with acute lymphoblastic leukemia and severe hepatic dysfunction.
    Robinson AC; Marini BL; Pettit KM; Perissinotti AJ
    J Oncol Pharm Pract; 2020 Jan; 26(1):200-205. PubMed ID: 30760167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Use of blinatumomab in children acute lymphoblastic leukemia in the Grand Ouest interregion: A chance for all].
    Camuset M; Grain A; Lorton F; Minckes O; Jourdain A; Millot F; Pellier I; Gandemer V; Battisti FR
    Bull Cancer; 2019 Mar; 106(3):206-215. PubMed ID: 30638898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.
    Raetz EA; Cairo MS; Borowitz MJ; Blaney SM; Krailo MD; Leil TA; Reid JM; Goldenberg DM; Wegener WA; Carroll WL; Adamson PC;
    J Clin Oncol; 2008 Aug; 26(22):3756-62. PubMed ID: 18669463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New monoclonal antibodies for the treatment of acute lymphoblastic leukemia.
    Farhadfar N; Litzow MR
    Leuk Res; 2016 Oct; 49():13-21. PubMed ID: 27521873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
    Ribera JM
    Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.